{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:13:52Z","timestamp":1789661632457,"version":"4.0.1"},"reference-count":54,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti\u2013amyloid-\u03b2 monoclonal antibodies represent a new class of disease-modifying therapies for Alzheimer's disease (AD). Their clinical adoption is complicated by amyloid-related imaging abnormalities (ARIA), encompassing vasogenic edema (ARIA-E) and hemorrhagic changes (ARIA-H). The comparative ARIA risk across agents and the influence of genetic factors remain incompletely characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To quantify the pooled incidence of ARIA-E and ARIA-H associated with anti\u2013amyloid-\u03b2 immunotherapies and to compare relative risks across agents using network meta-analytic modeling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Following PRISMA guidelines (PROSPERO: CRD420250653157), we searched PubMed, EMBASE, Scopus, Web of Science, and Ovid through January 2026 for Phase II\/III randomized controlled trials of anti\u2013amyloid-\u03b2 immunotherapies in AD. Random-effects models estimated pooled prevalence and odds ratios (ORs). A penalized likelihood network meta-analysis addressed sparse events.\n                      <jats:italic toggle=\"yes\">APOE<\/jats:italic>\n                      \u03b54\u2013stratified analyses and Bayesian sensitivity models were also performed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-two trials (up to 23,120 participants) were included. Pooled ARIA-E prevalence was 6.8% and ARIA-H was 15.8%, with substantial heterogeneity. Anti\u2013amyloid-\u03b2 therapy significantly increased odds of ARIA-E (OR 7.93; 95% CI 4.50\u201313.98) and ARIA-H (OR 1.87; 95% CI 1.28\u20132.72) versus placebo. The highest ARIA-E risk was seen with donanemab and aducanumab, followed by gantenerumab and lecanemab.\n                      <jats:italic toggle=\"yes\">APOE<\/jats:italic>\n                      \u03b54 carriage significantly elevated ARIA-E (OR 2.28) and ARIA-H (OR 2.07) risk, with a clear gene-dose effect in homozygotes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      ARIA risk varies substantially across anti\u2013amyloid-\u03b2 therapies and is strongly modulated by\n                      <jats:italic toggle=\"yes\">APOE<\/jats:italic>\n                      \u03b54 status. These findings support genotype-informed risk stratification and individualized MRI monitoring to optimize the benefit\u2013risk balance of disease-modifying therapies in AD.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13872877261466097","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T12:20:22Z","timestamp":1783772422000},"page":"65-82","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative risk of amyloid-related imaging abnormalities with anti\u2013amyloid-\u03b2 monoclonal antibodies: A systematic review and penalized likelihood network meta-analysis of randomized trials"],"prefix":"10.1177","volume":"113","author":[{"given":"Arkansh","family":"Sharma","sequence":"first","affiliation":[{"name":"Government Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1401-9154","authenticated-orcid":false,"given":"Vinay","family":"Suresh","sequence":"additional","affiliation":[{"name":"University of Oxford"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavan Raju","family":"Kola","sequence":"additional","affiliation":[{"name":"All India Institute of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishu","family":"Raj","sequence":"additional","affiliation":[{"name":"Atal Bihari Vajpayee Institute of Medical Sciences and Dr RML Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fnu","family":"Javairia","sequence":"additional","affiliation":[{"name":"Jinnah Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5781-2412","authenticated-orcid":false,"given":"Allimuthu","family":"Nithyanandam","sequence":"additional","affiliation":[{"name":"Tamil Nadu Government Multi-Super Speciality Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anmol","family":"Kaur","sequence":"additional","affiliation":[{"name":"Lady Hardinge Medical College and Associated Hospitals"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu","family":"Arora","sequence":"additional","affiliation":[{"name":"Netaji Subhash Chandra Bose Subharti Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Uwishema","sequence":"additional","affiliation":[{"name":"Oli Health Magazine Organization"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhanya","family":"Gorty","sequence":"additional","affiliation":[{"name":"Kamineni Academy of Medical Sciences and Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitya","family":"Beriwal","sequence":"additional","affiliation":[{"name":"University of Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amogh","family":"Verma","sequence":"additional","affiliation":[{"name":"Rama Medical College Hospital and Research Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Qidwai","sequence":"additional","affiliation":[{"name":"King George's Medical University, Lucknow, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardeep","family":"Singh Malhotra","sequence":"additional","affiliation":[{"name":"King George's Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Kumar Garg","sequence":"additional","affiliation":[{"name":"Era's Medical College and Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13016"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0281-2"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.5205"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02480-1"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.05.2351"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.21"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A3500"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.05.2351"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd7522"},{"key":"e_1_3_3_11_2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J 2021; 372: n71.","journal-title":"Br Med J"},{"key":"e_1_3_3_12_2","unstructured":"Rayyan: AI-Powered Systematic Review Management Platform https:\/\/www.rayyan.ai\/ (accessed 20 February 2026)."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.9562"},{"key":"e_1_3_3_14_2","unstructured":"RoB 2: A revised Cochrane risk-of-bias tool for randomized trials | Cochrane Bias https:\/\/methods.cochrane.org\/bias\/resources\/rob-2-revised-cochrane-risk-bias-tool-randomized-trials (accessed 20 February 2026)."},{"key":"e_1_3_3_15_2","article-title":"CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis","volume":"16","author":"Papakonstantinou T","year":"2020","unstructured":"Papakonstantinou T, Nikolakopoulou A, Higgins JPT, et al. CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis. Campbell Syst Rev 2020; 16: e1080.","journal-title":"Campbell Syst Rev"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003082"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.4161"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-016-0189-7"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-180675"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70043-0"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181c67808"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-017-0318-y"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304430"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00813-8"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01441-8"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2017.05.003"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2017.04.003"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312889"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705971"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2025.102981"},{"key":"e_1_3_3_33_2","article-title":"Clinical benefits and risks of antiamyloid antibodies in sporadic Alzheimer disease: systematic review and network meta-analysis with a web application","volume":"27","author":"Jeremic D","year":"2025","unstructured":"Jeremic D, Navarro-Lopez JD, Jimenez-Diaz L. Clinical benefits and risks of antiamyloid antibodies in sporadic Alzheimer disease: systematic review and network meta-analysis with a web application. J Med Intern Res 2025; 27: e68454.","journal-title":"J Med Intern Res"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2215148"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213483"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.681"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41583-023-00776-9"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-024-01053-8"},{"key":"e_1_3_3_39_2","unstructured":"16th Clinical Trials on Alzheimer\u2019s Disease (CTAD) Boston MA (USA) October 24\u201327 2023: Symposia | The Journal of Prevention of Alzheimer\u2019s Disease | Springer Nature Link https:\/\/link.springer.com\/article\/10.14283\/jpad.2022.129 (accessed 2 March 2026)."},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1559447"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70021"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-160369"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-018-0424-5"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005550"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2909"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.3937"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00024-9"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01441-8"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2017.05.003"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2017.04.003"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.09.224"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705971"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305032"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877261466097","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13872877261466097","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877261466097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:08:04Z","timestamp":1788253684000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13872877261466097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1177\/13872877261466097"],"URL":"https:\/\/doi.org\/10.1177\/13872877261466097","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]}}}